Evidence map›Paper›PMID 41732247›Full record

ArticleHeart rhythm O22026

Local modifications in tissular conditions before PFA increases acute lesion size.

Gerard Amorós-Figueras, Sergi Casabella-Ramón, Zoraida Moreno-Weidmann, Quim Castellví, Antoni Ivorra, Tomás García-Sánchez, Jose M Guerra

Abstract read
In one paragraph

Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gerard Amorós-FiguerasDepartment of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sergi Casabella-RamónDepartament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
Zoraida Moreno-WeidmannDepartment of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain.
Quim CastellvíDepartment of Engineering, Universitat Pompeu Fabra, Barcelona, Spain.
Antoni IvorraDepartment of Engineering, Universitat Pompeu Fabra, Barcelona, Spain.
Tomás García-SánchezDepartment of Engineering, Universitat Pompeu Fabra, Barcelona, Spain.
Jose M GuerraDepartment of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulsed field ablation (PFA) is a novel nonthermal cardiac ablation technology based on irreversible electroporation. Although calcium-enhanced electroporation to treat solid tumors has proved successful, the applicability of this technique to create deeper lesions in the left ventricle remains unknown. Objective: This study aimed to determine whether changes in local tissular conditions may have an impact on lesion formation in PFA. Methods: 5 anesthetized pigs received local epicardial injections of 200 mM calcium chloride (CaCl Results: We performed 31 ablations (21 CaCl Conclusion: In this proof-of-concept study, we show for the first time that changes in local tissular conditions may have an impact on lesion formation in PFA. The combination of calcium injection and PFA induced ventricular fibrillation in half of the applications.

Indexed as

Animal studyElectrophysiologyLesion sciencePulsed field ablationReversible electroporation

Identifiers

PMID41732247
PMCPMC12925757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.